

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Mark Chao, Ph.D.
Takeda Pharmaceuticals North America, Inc.
475 Half Day Road
Lincolnshire, IL 60069

In re Application of KAMIYAMA, et al.

Application No.: 10/517,847

PCT No.: PCT/JP03/07545

Int. Filing Date: 13 June 2003

Priority Date: 14 June 2002

Atty. Docket No.: 3082US0P

For: PRODRUG AND PROCESS FOR PRODUCING

SAME

DECISION ON PETITION

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 24 June 2005 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National Fee. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America. Further, a review of the application file reveals that all of the requirements of 35 U.S.C. 371 for entry into the national stage in the United States have been satisfied.

The application has an international filing date of 13 June 2003 under 35 U.S.C. 363 and will be given a date of 24 June 2005 under 35 U.S.C. 371(c)(1), (c)(2) and (c)(4).

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for treatment in accordance with this decision.

Derek A. Putonen Attorney Advisor

Office of PCT Legal Administration

Tel: (571) 272-3294 Fax: (571) 273-0459